Concepedia

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Daniel D. Mikol, Frederik Barkhof, Peter Chang, Patricia K. Coyle, Douglas Jeffery, Steven R. Schwid, Bettina Stubinski, Bernard M.J. Uitdehaag

The Lancet Neurology · 2008 · 484 citations · 28 references

Concepts

Life SciencesNeurologyPharmacotherapyImmunotherapyNeuroimmunologyRheumatologyDemyelinating DiseasesDemyelinating DisordersInterferon ResponsesInterferon-based TherapyMultiple SclerosisMultiple Sclerosis PharmacotherapyMultiple Sclerosis Symptom ManagementMultiple Sclerosis TherapyOpen-label TrialsRelapsing-remitting Multiple Sclerosis Treatment

References

28

Rating neurologic impairment in multiple sclerosis

John F. Kurtzke · Neurology · 1983 · 14.9K citations

Life Sciences, Neurology, Neuroscience +14

New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

Charles M. Poser, Donald W. Paty, Labe C. Scheinberg et al. · Annals of Neurology · 1983 · 7.4K citations

Life Sciences, Neurology, Neuroscience +12

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

W. I. McDonald, Alistair Compston, Gilles Edan et al. · Annals of Neurology · 2001 · 7K citations

Medicine, Internal Medicine, Neurology +10

Defining the clinical course of multiple sclerosis

Fred Lublin, Stephen C. Reingold · Neurology · 1996 · 3.7K citations

Medicine, Neurology, Pathology +17

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Chris H. Polman, Paul O’Connor, Eva Havrdová et al. · New England Journal of Medicine · 2006 · 3.3K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14